Literature DB >> 18555553

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.

Kathrin Overbeck1, Daniel Genné, Alain Golay, Francesco Negro.   

Abstract

BACKGROUND/AIMS: Insulin resistance reduces the response to interferon alfa-based therapy of chronic hepatitis C patients. It has been speculated that improvement of insulin sensitivity might increase the chances of responding to treatment of such individuals.
METHODS: We started a multicenter clinical trial of retreatment of chronic hepatitis C patients, who had failed to respond to the pegylated interferon alfa/ribavirin combination, with a triple therapy consisting in these same antivirals plus an insulin-sensitizer (pioglitazone) (The INSPIRED-HCV study).
RESULTS: None of the first five patients fulfilling the inclusion criteria and included in the trial achieved a satisfactory virological response after 12 weeks of retreatment, despite the fact that in at least three of them the insulin resistance score improved. As a result, the study was terminated.
CONCLUSIONS: Different schedules are warranted to improve insulin sensitivity prior to attempting retreatment of chronic hepatitis C patients with insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555553     DOI: 10.1016/j.jhep.2008.03.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  24 in total

1.  Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.

Authors:  Marie-Louise C Vachon; Stephanie H Factor; Andrea D Branch; Maria-Isabel Fiel; Maribel Rodriguez-Torres; Norbert Bräu; Richard K Sterling; Jihad Slim; Andrew H Talal; Douglas T Dieterich; Mark S Sulkowski
Journal:  J Hepatol       Date:  2010-08-21       Impact factor: 25.083

Review 2.  Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.

Authors:  Hong Sheng Cheng; Wei Ren Tan; Zun Siong Low; Charlie Marvalim; Justin Yin Hao Lee; Nguan Soon Tan
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

Review 3.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 4.  The interaction between HCV and nuclear receptor-mediated pathways.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Yvonne Wan
Journal:  Pharmacol Ther       Date:  2011-05-18       Impact factor: 12.310

Review 5.  Hepatitis C virus infection and insulin resistance.

Authors:  Sandip K Bose; Ranjit Ray
Journal:  World J Diabetes       Date:  2014-02-15

6.  Insulin resistance and chronic liver disease.

Authors:  Takumi Kawaguchi; Eitaro Taniguchi; Minoru Itou; Masahiro Sakata; Shuji Sumie; Michio Sata
Journal:  World J Hepatol       Date:  2011-05-27

7.  Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.

Authors:  Kristen M Marks; Douglas Kitch; Raymond T Chung; Colleen Hadigan; Janet Andersen; Phyllis Tien; Annie Luetkemeyer; Beverly Alston-Smith; Marshall J Glesby
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

8.  Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load.

Authors:  Toshihiko Mizuta; Yasunori Kawaguchi; Yuichiro Eguchi; Hirokazu Takahashi; Keisuke Ario; Takumi Akiyama; Noriko Oza; Taiga Otsuka; Takuya Kuwashiro; Toru Yoshimura; Akitaka Hisatomi; Iwata Ozaki
Journal:  Dig Dis Sci       Date:  2009-01-30       Impact factor: 3.199

Review 9.  Molecular mechanisms of insulin resistance in chronic hepatitis C.

Authors:  Mark W Douglas; Jacob George
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

10.  Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance.

Authors:  Francesco Negro
Journal:  PPAR Res       Date:  2009-01-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.